comparemela.com
Home
Live Updates
Medtronic Evolut TAVR Platform Outperforms Surgery with Sustained Valve Performance for Low-risk Patients at Four Years : comparemela.com
Medtronic Evolut TAVR Platform Outperforms Surgery with Sustained Valve Performance for Low-risk Patients at Four Years
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial
Related Keywords
Nina Goodheart ,
Michael Reardon ,
Medtronic Evolut ,
Medtronic ,
Cardiovascular Research Foundation ,
Journal Of The American College Cardiology ,
Cardiovascular Research ,
Evolut Low Risk ,
Transcatheter Cardiovascular Therapeutics ,
American College ,
Allison Family Distinguished Chair ,
Houston Methodist Hospital ,
Low Risk Trial ,
Structural Heart ,
Cardiovascular Portfolio ,
comparemela.com © 2020. All Rights Reserved.